Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research & Development In Brief

This article was originally published in The Tan Sheet

Executive Summary

Vitamin D benefits cancer patients: A study in the British Journal of Cancer concluded that higher 25-hydroxyvitamin D3 levels in 1,017 patients diagnosed with colorectal cancer are associated with a significant reduction in colorectal cancer-specific and overall mortality. Published online Aug. 18, the study conducted by researchers at the Dana-Farber Cancer Institute in Boston assessed the amount of vitamin D in patients' blood at the time of diagnosis and concluded patients with higher vitamin D scores were 50 percent less likely to die from the disease than those with lower scores. An earlier study found a link between high vitamin D levels and decreased risk of developing colon cancer, and a report published in the August 2007 issue of Nutrition Review stated that universal intake of 2,000 IU per day of vitamin D3 would lower North American colon cancer incidence by about 50 percent (1"The Tan Sheet" Sept. 10, 2007). Separately, a cohort study published in the Sept. 21 online edition of the Journal of Clinical Oncology found melanoma patients with higher levels of 25-hydroxyvitamin D3 were less likely to suffer a relapse and death than those with lower levels. Conducted by a research team led by Julia Newton-Bishop, Leeds Institute of Molecular Medicine, England, the study also found reoccurring tumors were thinner in patients with higher levels of the vitamin. The study, which confirmed findings of an earlier retrospective study, followed 872 patients over a period of 4.7 years

You may also be interested in...



P&G Defends Tooth-Whitening Cosmetic Classification In FDA Letter

Procter & Gamble urges FDA to deny a citizen petition by the American Dental Association to reclassify commercially available tooth whiteners as drugs, saying the petition is motivated by the financial interests of ADA members

P&G Defends Tooth-Whitening Cosmetic Classification In FDA Letter

Procter & Gamble urges FDA to deny a citizen petition by the American Dental Association to reclassify commercially available tooth whiteners as drugs, saying the petition is motivated by the financial interests of ADA members

P&G Defends Tooth Whitening Cosmetic Classification In FDA Letter

Procter & Gamble urges FDA to deny a citizen petition by the American Dental Association to reclassify commercially available tooth-whiteners as drugs, saying ADA members' financial interests motivated the petition

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103394

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel